204 related articles for article (PubMed ID: 9929505)
21. Preclinical pharmacology of epothilone D, a novel tubulin-stabilizing antitumor agent.
Wang H; Wang Z; Wang S; Li M; Nan L; Rhie JK; Covey JM; Zhang R; Hill DL
Cancer Chemother Pharmacol; 2005 Sep; 56(3):255-60. PubMed ID: 15868148
[TBL] [Abstract][Full Text] [Related]
22. Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human.
Halpin RA; Ulm EH; Till AE; Kari PH; Vyas KP; Hunninghake DB; Duggan DE
Drug Metab Dispos; 1993; 21(6):1003-11. PubMed ID: 7905377
[TBL] [Abstract][Full Text] [Related]
23. Inter-species comparison of liver and small intestinal microsomal metabolism of fluoranthene.
Walker SA; Whitten LB; Seals GB; Lee WE; Archibong AE; Ramesh A
Food Chem Toxicol; 2006 Mar; 44(3):380-7. PubMed ID: 16182425
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and metabolism of a RAS farnesyl transferase inhibitor in rats and dogs: in vitro-in vivo correlation.
Singh R; Chen IW; Jin L; Silva MV; Arison BH; Lin JH; Wong BK
Drug Metab Dispos; 2001 Dec; 29(12):1578-87. PubMed ID: 11717177
[TBL] [Abstract][Full Text] [Related]
25. Metabolism of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737): identification of an unusual N-acetylglucosamine conjugate in the cynomolgus monkey.
Johnson BM; Kamath AV; Leet JE; Liu X; Bhide RS; Tejwani RW; Zhang Y; Qian L; Wei DD; Lombardo LJ; Shu YZ
Drug Metab Dispos; 2008 Dec; 36(12):2475-83. PubMed ID: 18787055
[TBL] [Abstract][Full Text] [Related]
26. Glucuronidation of anti-HIV drug candidate bevirimat: identification of human UDP-glucuronosyltransferases and species differences.
Wen Z; Martin DE; Bullock P; Lee KH; Smith PC
Drug Metab Dispos; 2007 Mar; 35(3):440-8. PubMed ID: 17151190
[TBL] [Abstract][Full Text] [Related]
27. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and enhanced bioavailability of candidate cancer preventative agent, SR13668 in dogs and monkeys.
Kapetanovic IM; Muzzio M; Hu SC; Crowell JA; Rajewski RA; Haslam JL; Jong L; McCormick DL
Cancer Chemother Pharmacol; 2010 May; 65(6):1109-16. PubMed ID: 19756605
[TBL] [Abstract][Full Text] [Related]
29. In vivo metabolism of [14C]ruboxistaurin in dogs, mice, and rats following oral administration and the structure determination of its metabolites by liquid chromatography/mass spectrometry and NMR spectroscopy.
Barbuch RJ; Campanale K; Hadden CE; Zmijewski M; Yi P; O'Bannon DD; Burkey JL; Kulanthaivel P
Drug Metab Dispos; 2006 Feb; 34(2):213-24. PubMed ID: 16258078
[TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo metabolism of desogestrel in several species.
Verhoeven CH; Krebbers SF; Wagenaars GN; Vos RM
Drug Metab Dispos; 1998 Sep; 26(9):927-36. PubMed ID: 9733673
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological activities of topoisomerase I inhibitors, 6-N-amino analogues of NB-506.
Ohkubo M; Kojiri K; Kondo H; Tanaka S; Kawamoto H; Nishimura T; Nishimura I; Yoshinari T; Arakawa H; Suda H; Morishima H; Nishimura S
Bioorg Med Chem Lett; 1999 May; 9(9):1219-24. PubMed ID: 10340602
[TBL] [Abstract][Full Text] [Related]
32. An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymes.
Nassar AE; King I; Paris BL; Haupt L; Ndikum-Moffor F; Campbell R; Usuki E; Skibbe J; Brobst D; Ogilvie BW; Parkinson A
Drug Metab Dispos; 2009 Sep; 37(9):1922-30. PubMed ID: 19520774
[TBL] [Abstract][Full Text] [Related]
33. Metabolism of prazosin in rat, dog, and human liver microsomes and cryopreserved rat and human hepatocytes and characterization of metabolites by liquid chromatography/tandem mass spectrometry.
Erve JC; Vashishtha SC; DeMaio W; Talaat RE
Drug Metab Dispos; 2007 Jun; 35(6):908-16. PubMed ID: 17353349
[TBL] [Abstract][Full Text] [Related]
34. Utility of the carboxylesterase inhibitor bis-para-nitrophenylphosphate (BNPP) in the plasma unbound fraction determination for a hydrolytically unstable amide derivative and agonist of the TGR5 receptor.
Eng H; Niosi M; McDonald TS; Wolford A; Chen Y; Simila ST; Bauman JN; Warmus J; Kalgutkar AS
Xenobiotica; 2010 Jun; 40(6):369-80. PubMed ID: 20297923
[TBL] [Abstract][Full Text] [Related]
35. Characterization of deltamethrin metabolism by rat plasma and liver microsomes.
Anand SS; Bruckner JV; Haines WT; Muralidhara S; Fisher JW; Padilla S
Toxicol Appl Pharmacol; 2006 Apr; 212(2):156-66. PubMed ID: 16169030
[TBL] [Abstract][Full Text] [Related]
36. Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data.
Iwatsubo T; Suzuki H; Sugiyama Y
J Pharmacol Exp Ther; 1997 Nov; 283(2):462-9. PubMed ID: 9353358
[TBL] [Abstract][Full Text] [Related]
37. The anti-inflammatory activity of 5H-dibenz[c,e]azepine-5,7(6H)dione, 6,7-dihydro-5H-dibenz[c,e]azepine, N-benzoylbenzamide and 1H-benz[d,e]isoquinoline-1,3(2H)dione derivatives in rodents.
Hall IH; Simlot R; Oswald CB; Murthy AR; elSourady H; Chapman JM
Acta Pharm Nord; 1990; 2(6):387-400. PubMed ID: 2095797
[TBL] [Abstract][Full Text] [Related]
38. Structural characterization of anti-HIV drug candidate PA-457 [3-O-(3',3'-dimethylsuccinyl)-betulinic acid] and its acyl glucuronides in rat bile and evaluation of in vitro stability in human and animal liver microsomes and plasma.
Wen Z; Stern ST; Martin DE; Lee KH; Smith PC
Drug Metab Dispos; 2006 Sep; 34(9):1436-42. PubMed ID: 16751262
[TBL] [Abstract][Full Text] [Related]
39. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.
Beconi MG; Reed JR; Teffera Y; Xia YQ; Kochansky CJ; Liu DQ; Xu S; Elmore CS; Ciccotto S; Hora DF; Stearns RA; Vincent SH
Drug Metab Dispos; 2007 Apr; 35(4):525-32. PubMed ID: 17220241
[TBL] [Abstract][Full Text] [Related]
40. Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl.
Li M; Wang H; Hill DL; Stinson S; Veley K; Grossi I; Peggins J; Covey JM; Zhang R
Cancer Chemother Pharmacol; 2006 May; 57(5):607-14. PubMed ID: 16331493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
